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introduction: Schizophrenia is a severe, debilitating mental disorder that affects both 
the physical health and the functional capacity of patients, causing great impairment 
throughout the life course. Although physical and cognitive impairments may represent 
different expressions of a single systemic inflammatory process, little is known about the 
relationship between motor function and schizophrenia.
Objective: To evaluate physical functional capacity in patients with schizophrenia and 
ascertain whether it correlates with markers of inflammation, disease severity, and 
pharmacotherapy.
Methods: Cross-sectional study using a convenience sampling strategy. Forty patients with 
stable schizophrenia, undergoing treatment, were recruited from the Outpatient Program 
of Hospital de Clínicas de Porto Alegre, University Hospital linked to Public Health System. 
Physical functional capacity was assessed by the 6-min walk test (6MWT), and inflamma-
tory markers were measured by C-reactive protein (CRP) and Von Willebrand factor.
results: Mean functional capacity and clinical variables differed among patients and 
Brazilian population regarding heart rate (p = 0.004), diastolic (p = 0.001) and systolic 
(p < 0.001) blood pressure, respiratory rate (p < 0.001), CRP (p = 0.015), Borg Scale of 
Perceived Exertion scores (BSPE) (p < 0.001), and 6MWT both in men (p < 0.001) and 
women (p = 0.024). Additionally, 6MWT and dyspnea in BSPE were positively associated 
with CRP (r = −0.369, p = 0.019) and (r = −0.376, p = 0.017) and (r = 0.354, p = 0.025 
and r = 0.535, p < 0.001, respectively).
conclusion: The present study detected significant association between measures of 
functional impairment and markers of inflammation, especially elevated CRP in a group 
of stable outpatients with DSM-IV and ICD10 diagnosis of schizophrenia. Possible expla-
nations for the associations could be linked to continued use of antipsychotics, although 
underlying neuroinflammatory mechanisms directly related to illness (schizophrenia) 
could not be ruled out. The findings of this study expand evidences of neuroinflammation 
to systemic inflammation in schizophrenia linking it to alterations of physical functional 
capacity and point to the need of additional studies exploring general inflammation and 
novel therapeutic interventions.
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inTrODUcTiOn
Despite increased morbidity and mortality in schizophrenia, 
patients still have limited access to health care and less oppor-
tunity to receive adequate prevention and treatment than 
non-schizophrenic population. Mean functional motor capacity 
is reduced in 20% compared to general population resulting in 
overall reduction of global functioning (1, 2).
Persons with schizophrenia have increased risk of obesity, 
probably due to sedentary lifestyle, inappropriate dietary choices, 
and adverse effects of psychiatric drugs (3, 4). Mortality is 2.4-fold 
higher than in the general population after excluding death from 
unnatural causes (5). Furthermore, studies show that patients 
with schizophrenia have limited access to general health care and 
fewer opportunities for prevention and treatment than would be 
expected in a non-psychiatric population (6).
The etiology of schizophrenia is still unclear, but several 
patients have reported abnormalities of immune response 
in patients with the condition, and have suggested that the 
neuroinflammatory response to immune reactions may play a 
crucial role in the pathogenesis of schizophrenia (7). There are 
strong hypotheses arguing for increased inflammatory markers 
due to microglia activation, causing abnormal neurogenesis, 
neural degradation, and white matter abnormalities, and thus 
playing a major role in the pathogenesis of schizophrenia (2, 8). 
An increase in proinflammatory cytokines, such as C-reactive 
protein (CRP), may also correlate with risk of metabolic disease 
and disease severity (9, 10), possibly including ability to perform 
physical tasks, integrate into social activities, perform activities 
of daily life (ADL), and increase overall quality of life (QOL) 
(11). Recently found that sedentary behavior is associated with 
increased CRP levels and marker of cardiovascular disease in 
people with psychosis (12). Patients with diagnosis of schizo-
phrenia can perform inexpensive, easy, and rapid tests of func-
tional capacity, like the 6-min walk test (6MWT), and provide 
relevant data about functional capacity (13, 14). The objective 
of the present study was to test if physical functional capacity in 
patients with schizophrenia correlates with common inflamma-
tory markers, such as CRP and Von Willebrand factor (VWF). 
The main study hypothesis was that patients with schizophrenia 
would display association of raised levels of these markers with 
reduced functional capacity.
MaTerials anD MeThODs
The study displayed a cross-sectional design in a convenience 
sample of stable outpatients with simultaneous DSM-IVTR and 
ICD10 diagnosis of schizophrenia under public Health Care in 
an outpatient psychiatric clinic at a major teaching Hospital in 
Southern Brazil (Hospital de Clínicas de Porto Alegre – HCPA).
All participants had a confirmed diagnosis of schizophrenia, 
established over the course of at least four encounters involving 
information from both patient and their family members, with 
ages of 18–60 years, under stable psychopharmacological therapy 
tailored to their clinical condition. Patients were excluded if 
they had a history of alcohol or other drug abuse during the 
preceding month, a history of head trauma with posttraumatic 
amnesia, systemic or neurologic disease, current use of medica-
tion capable of inducing psychopathological manifestations, with 
present suicide risk, pregnant or lactating, with autoimmune 
conditions, taking steroidal anti-inflammatory drugs, or refusing 
to take part in the study. Participants completed the 6MWT, and 
underwent clinical assessment, and blood samples were collected 
at the HCPA Clinical Pathology Service as per routine laboratory 
practice. CRP was assayed by nephelometry (reference range: 
<5.0 mg/L = non-reactive; ≥5.0 mg/L = reactive), and vWF, by 
immunoturbidimetry (reference range: 50–160%).
Six-minute walk test was carried out in accordance with 
American Thoracic Society guidelines, along a hallway containing 
minimal external stimuli, with demarcated turnaround points, by 
two previously trained technicians. Participants were instructed 
to walk as briskly as possible, without running, during the 6-min 
test period. They were allowed to stop as necessary, but were noti-
fied that the timer would continue to run down. During the test, 
the technicians used standard words of encouragement. Blood 
pressure, heart rate (HR), respiratory rate, peripheral oxygen 
saturation, and dyspnea measured by Borg perceived exertion 
scale scores were measured both at the start and at the end of the 
test. Additionally, HR and blood oxygen saturation (BOS) were 
also measured at minute 3. Results were interpreted by means of 
the Enright and Sherrill algorithms for predicted 6MWD with 
upper and lower limits for sex, height, age, and weight.
Statistical analyses were carried out by SPSS 21.0 Software 
licensed to UFRGS. Variables were tested for normality by 
Kolmogorov–Smirnov test, and mean differences calculated 
by t-test for independent samples, Student’s t-test to compare 
sample means to general population, Chi-square test to analyze 
categorical variables, and Pearson or Spearman correlation coef-
ficients as appropriate to test for associations among variables. 
The significance level was set at 0.05.
ethics statement
The study was approved by the HCPA Research Ethics Committee 
with registry number 110083 in November 2011. Patients who 
agreed to take part in the study provided written informed con-
sent. Furthermore, all patients were required to bring a chaperone 
or legal guardian signing the consent form and observe all data 
collection procedures.
resUlTs
From 415 patients in the HCPA Schizophrenia Program reg-
istry, 213 were not under present care. The 202 patients under 
regular care received a telephone-based screening interview, 
which excluded 162 patients due to study requirements, with 
a final sample of 40, 18% woman and 82% men (Figure  1). 
Socio-demographic characteristics were normally distributed 
and homogeneous across the two disease duration subgroups 
defined by data distribution (≤7 years and >7 years), as shown 
in Table 1. The only significant difference was found in marital 
status: patients in the >7-year disease duration group were more 
likely to be single or separated (Table 1).
Mean respiratory rate, BOS, blood pressure, and 6MWD 
in male and female patients were below measures of general 
TaBle 1 | socio-demographic and clinical characteristics of outpatients 
with stable schizophrenia (n = 40).
Variable illness ≤7 years illness >7 years Test p
Age 32.83 ± 7.48 37.93 ± 8.64 Independent t 0.084
BMI 26.59 ± 5.26 27.51 ± 3.85 Independent t 0.539
Smoking 9/12 18/28 Chi-square 0.716
≤8 years  
Educ
4/12 14/28 Chi-square 0.268
Clozapine/
other
8/12 21/28 Chi-square 0.704
Single/
separated
9/12 28/28 Chi-square 0.022
BMI, body mass index.
Disease duration (25th percentile = 7 years). Age and BMI normally distributed.
FigUre 1 | recruitment flowchart. Patients with schizophrenia under regular care at the outpatient Program of Hospital de Clínicas de Porto Alegre (HCPA) 
recruited from January 2012 to December 2013.
TaBle 2 | comparison of mean clinical and functional variables in 
patients with stable schizophrenia (n = 40) and population averages.







HR (bpm) 92.00 80.00 15.00 0.004
Diastolic BP (mmHg) 74.50 85.00 12.35 0.001
Systolic BP (mmHg) 114.25 130.00 12.12 <0.001
BOS (%) 95.13 97.50 2.43 0.338
RR (bpm) 12.88 17.00 24.23 <0.001
CRP (mg/L) 6.18 4.00 54.50 0.015
vWF (%) 107.10 105.00 2.00 0.712
BDS scale 0–10 2.21 1.00 121.00 0.005
6MWT, males (m) 3.85 5.76 33.16 <0.001
6MWT, females (m) 4.04 4.94 19.22 0.024
6MWT, 6-min walk test.
Population means: HR, heart rate (15); BP, blood pressure – diastolic and systolic 
(15); BOS, blood oxygen saturation (16); RR, respiratory rate (17); BDS, Borg dyspnea 
scale, and 6MWT, 6 min walking test (18).
Population means for C-reactive protein (CRP) and von Willebrand factor (vWF) 
obtained from the HCPA laboratory (unpublished data).
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population. HR and CRP and vWF levels were higher in clinical 
sample compared to general population (Table 2).
Patients were stratified by disease duration according to 25th 
percentile, and medications in two categories (clozapine or other 
neuroleptics).
Performance on 6MWD ranged from 0 to 610 m (Figure 2). 
Upper and lower limits of predicted 6MWD were 379.29–796.37 m 
and 240.29–643.37 m, respectively. Only 7.5% of patients (3 of 
40) were reached the minimum predicted distance. Male mean 
6MWD was 385 m, significantly lower than the population aver-
age of 576 m (p < 0.001), and Female performance was 404 m, 
also significantly above general population scores of 494  m 
(p = 0.024).
Correlation analysis of functional performance variables 
showed that impaired 6MWD (difference between actual and 
predicted distance) and dyspnea on the Borg scale were corre-
lated to CRP (r = −0.369, p = 0.019 and r = −0.376, p = 0.017 
and r = 0.354, p = 0.025 and r = 0.535, p < 0.001, respectively). 
These associations were stronger after controlling for smoking, 
age, and sex.
DiscUssiOn
Although previous studies have identified reduced physical func-
tional capacity in patients with schizophrenia by the 6MWT and 
other publications demonstrated the role of inflammatory mark-
ers in schizophrenia, this was the first study to detect association 
of reduced functional capacity (measured by HR, blood pressure, 
BOS, respiratory rate, and 6MWD) with increased inflammatory 
FigUre 2 | six-minute walking test (actual and predicted distance) in 40 patients with stable schizophrenia: 6MWD-lln, predicted 6-min walk 
distance (lower limit of normal). 6MWD, actual 6-min walk distance. 6MWD-ULN, predicted 6-min walk distance (upper limit of normal). Predicted values were 
computed using the Enright algorithm (19).
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marker (CRP). By contrast, vWF, a reliable marker of endothelial 
dysfunction, were not significantly different from population 
levels, in contrast to Hope (17) of increased vWF in patients with 
schizophrenia compared to healthy controls (p < 0.05), increased 
vWF associated with small increase of CRP, and CRP and vWF 
positively associated with disease severity.
Body mass index and BP were not associated with physical 
functional capacity, suggesting that all patients were under 
adequate treatment, stable and well informed about illness and 
potential metabolic consequences. It is also of note that the usual 
treatment provided by the Outpatient Program includes dietary 
guidance.
In the sample of patients with schizophrenia included in this 
study, males and females had 30 and 20% reductions in func-
tional capacity, respectively, corroborating Vancampfort (20) 
data of 20% reduction of 6MWD compared to healthy controls 
(p < 0.001). Additionally, Martín-Sierra (21) noted that impaired 
functional performance was associated with increased weight, 
metabolic complications, poor muscle fitness, smoking, negative 
symptoms, depressive symptoms, antipsychotic therapy, and 
reduced QOL. In the present study, smoking and antipsychotic 
use were not associated with reduced functional performance.
Dyspnea (Borg scale) in the sample was 121% higher than the 
national average. Vancampfort (20) found that severely mentally 
ill patients exhibited reduced forced expiratory volume in 1  s 
(FEV1) and forced vital capacity (FVC) compared to healthy 
controls, also associated with metabolic complications (22).
Among the different inflammatory markers, CRP holds a 
prominent position in severe psychiatric conditions, and par-
ticularly in schizophrenia. In the present study, elevated CRP 
levels were associated with functional impairment. In a 2014 
review, Singh analyzed the current evidence for the role of CRP 
in schizophrenia, identifying increased CRP in 14 of 16 studies. 
Vuksan-Cusa (23) also reported elevated CRP levels associated 
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with the risk of new onset metabolic syndrome. In the present 
sample, CRP levels were not associated with BMI (no other fac-
tors of metabolic disease were assessed in the study).
Dickerson (24), using a high-sensitivity CRP test (unlike 
conventional CRP testing as used in the present study), found 
elevated levels of CRP in patients with schizophrenia compared 
to healthy controls (p < 0.001). Comparison of bipolar patients 
disorder with normal controls failed to show difference, even after 
adjustment with logistic regression models.
Blood pressure was below the population average in the 
present sample. These results can be explained by the findings 
of Mackin (25), who reviewed cardiac effects of antipsychotic 
agents and reported association of clozapine therapy with 
orthostatic hypotension, probably due to the antagonist effect of 
clozapine with cholinergic and α1-adrenergic receptors, and with 
abnormalities of cardiac repolarization (specifically, prolonged 
ventricular repolarization). The same study also showed that 
clozapine associated with bradicardia, supporting the decreased 
HR observed in the present sample.
Overall, 72% of the 144 who completed the telephone interview 
did not participate due to failure to attend to the medical appoint-
ment in two consecutive days (only family members attended), 
recent participation in other studies, or some physical disability.
Limitations of the present study include the small sample 
size, failure to include additional clinical scales (BPRS, PANSS, 
Hamilton or Beck depression scales, etc.), the use of conventional 
CRP rather than high-sensitivity CRP assays, the lack of simul-
taneous assessment of metabolic variables (such as glucose, cho-
lesterol, and triglyceride levels) and the lack of a control group. 
Furthermore, there was no record of specific medications used 
other than neuroleptics, and additional inflammation markers 
other than CRP and vWF, including cytokines and chemokines. 
It is advisable to surmount these deficiencies in future studies, 
including additional Clinical scales, inflammatory markers, and 
metabolic parameters.
In summary, the present study revealed an association 
between impaired physical functional capacity and increased 
CRP inflammatory marker in patients with schizophrenia, a 
complex condition with both physical and mental consequences. 
If reinforced by additional studies, it could also point to expanded 
treatment guidelines and protocols, including multidisciplinary 
and multi-systemic approach of patients with diagnosis of schizo-
phrenia. Involvement of other professionals, such as physical 
therapists, trained to assess and treat functional impairments 
could then contribute to improved understanding and manage-
ment of mental and physical health of patients with diagnosis of 
schizophrenia.
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